top of page
The Professional Network for Healthcare Experts
FDA grants final approval to Bravnetsa for SSTR-positive GEP-NETs
The FDA has granted final approval to Lantheus' Bravnetsa for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.
nuaxia
Sep 231 min read
FDA approves Curium's Bexlutry as first radioligand equivalent for SSTR-positive GEP-NETs
The FDA has approved Curium's Bexlutry as the first radioligand equivalent to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.
nuaxia
Sep 161 min read
bottom of page